|
May 15
|
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
|
|
May 9
|
Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
|
|
May 8
|
Neuronetics, Inc. (NASDAQ:STIM) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Neuronetics Inc (STIM) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth Amidst ...
|
|
May 8
|
Q1 2024 Neuronetics Inc Earnings Call
|
|
May 7
|
Neuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing Losses
|
|
May 7
|
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 7
|
Neuronetics Reports Record First Quarter 2024 Financial and Operating Results
|
|
May 1
|
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
|
|
Apr 23
|
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
|
|
Apr 10
|
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
|
|
Apr 1
|
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
|
|
Mar 27
|
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 27
|
Neuronetics wins FDA clearance for device to treat adolescents with depression
|
|
Mar 25
|
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
|
|
Mar 8
|
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
|
|
Mar 7
|
Neuronetics Inc (STIM) Reports Record Revenues in Q4 and Full Year 2023
|
|
Mar 7
|
Neuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Call Transcript
|
|
Mar 7
|
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
|
|
Mar 6
|
Neuronetics Full Year 2023 Earnings: US$1.05 loss per share (vs US$1.38 loss in FY 2022)
|